JP5883027B2 - 神経学的疾患治療法、ならびにそのための組成物および物質 - Google Patents

神経学的疾患治療法、ならびにそのための組成物および物質 Download PDF

Info

Publication number
JP5883027B2
JP5883027B2 JP2013546331A JP2013546331A JP5883027B2 JP 5883027 B2 JP5883027 B2 JP 5883027B2 JP 2013546331 A JP2013546331 A JP 2013546331A JP 2013546331 A JP2013546331 A JP 2013546331A JP 5883027 B2 JP5883027 B2 JP 5883027B2
Authority
JP
Japan
Prior art keywords
decorin
pharmaceutical composition
injury
spinal cord
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013546331A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014500327A5 (cg-RX-API-DMAC10.html
JP2014500327A (ja
Inventor
デイビス，スティーブン
マイナー，ケネス・ハル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scidec LLC
Original Assignee
Scidec LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scidec LLC filed Critical Scidec LLC
Publication of JP2014500327A publication Critical patent/JP2014500327A/ja
Publication of JP2014500327A5 publication Critical patent/JP2014500327A5/ja
Application granted granted Critical
Publication of JP5883027B2 publication Critical patent/JP5883027B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2013546331A 2010-12-20 2011-12-20 神経学的疾患治療法、ならびにそのための組成物および物質 Active JP5883027B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061424769P 2010-12-20 2010-12-20
US61/424,769 2010-12-20
PCT/US2011/066199 WO2012088133A1 (en) 2010-12-20 2011-12-20 Methods for treating neurological conditions and compositions and materials therefor

Publications (3)

Publication Number Publication Date
JP2014500327A JP2014500327A (ja) 2014-01-09
JP2014500327A5 JP2014500327A5 (cg-RX-API-DMAC10.html) 2015-02-12
JP5883027B2 true JP5883027B2 (ja) 2016-03-09

Family

ID=46235329

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013546331A Active JP5883027B2 (ja) 2010-12-20 2011-12-20 神経学的疾患治療法、ならびにそのための組成物および物質

Country Status (6)

Country Link
US (3) US9061047B2 (cg-RX-API-DMAC10.html)
EP (1) EP2654899B1 (cg-RX-API-DMAC10.html)
JP (1) JP5883027B2 (cg-RX-API-DMAC10.html)
AU (1) AU2011349256B2 (cg-RX-API-DMAC10.html)
ES (1) ES2582605T3 (cg-RX-API-DMAC10.html)
WO (1) WO2012088133A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011349256B2 (en) 2010-12-20 2017-01-05 Scidec Therapeutics, Inc. Methods for treating neurological conditions and compositions and materials therefor
WO2015089443A2 (en) * 2013-12-12 2015-06-18 The Brigham And Women's Hospital, Inc. Treating neurodegenerative disease
CN104173938B (zh) * 2014-08-29 2017-03-01 李从达 一种治疗脊髓栓系综合征的中药制剂
GB202314158D0 (en) * 2023-09-15 2023-11-01 Senorei Ltd Inhibition of vascular leakage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612038B2 (en) 1999-11-18 2009-11-03 Brown University Biglycan and related therapeutics and methods of use
US8419710B2 (en) 2006-12-06 2013-04-16 Medtronic, Inc. Methods for infusing fluids via an implantable infusion system
JP2010047533A (ja) * 2008-08-22 2010-03-04 Mitsubishi Gas Chemical Co Inc 脊髄損傷改善剤
WO2010065917A1 (en) * 2008-12-05 2010-06-10 The Regents Of The University Of California Methods of treating neurological disorders
AU2011349256B2 (en) * 2010-12-20 2017-01-05 Scidec Therapeutics, Inc. Methods for treating neurological conditions and compositions and materials therefor

Also Published As

Publication number Publication date
EP2654899A4 (en) 2014-08-20
ES2582605T3 (es) 2016-09-14
EP2654899A1 (en) 2013-10-30
US20170136098A1 (en) 2017-05-18
EP2654899B1 (en) 2016-05-25
JP2014500327A (ja) 2014-01-09
US20150250859A1 (en) 2015-09-10
US20120157976A1 (en) 2012-06-21
US9061047B2 (en) 2015-06-23
US9592276B2 (en) 2017-03-14
US10258670B2 (en) 2019-04-16
AU2011349256B2 (en) 2017-01-05
WO2012088133A1 (en) 2012-06-28
HK1190652A1 (zh) 2014-07-11

Similar Documents

Publication Publication Date Title
Xie et al. Exendin-4 attenuates neuronal death via GLP-1R/PI3K/Akt pathway in early brain injury after subarachnoid hemorrhage in rats
De Albornoz et al. Non-surgical therapies for peripheral nerve injury
Alder et al. Genetic and pharmacological intervention of the p75NTR pathway alters morphological and behavioural recovery following traumatic brain injury in mice
Shields et al. Benefit of chondroitinase ABC on sensory axon regeneration in a laceration model of spinal cord injury in the rat
CA3000985A1 (en) Method for treating neurodegenerative diseases
US10258670B2 (en) Methods for treating neurological conditions and compositions and materials therefor
Eggers et al. Clinical and neurobiological advances in promoting regeneration of the ventral root avulsion lesion
US20050152995A1 (en) Methods and compositions for promoting axon regeneration and cell replacement therapy
CN109715194B (zh) 用于治疗神经障碍的颤蛋白组合物
JP2006521405A (ja) 発作回復におけるエリトロポイエチンの使用
Wen et al. Low-intensity pulsed ultrasound enhanced neurite guidance growth through Netrin-1/DCC signal pathway in primary cultured cortical neurons of rats
Li et al. Regeneration of olfactory neuroepithelium in 3-methylindole-induced anosmic rats treated with intranasal chitosan
AU2011349256A1 (en) Methods for treating neurological conditions and compositions and materials therefor
Yao et al. Transcranial pulsed current stimulation alleviates neuronal pyroptosis and neurological dysfunction following traumatic brain injury via the orexin-A/NLRP3 pathway
Ying et al. Gelatine nanostructured lipid carrier encapsulated FGF15 inhibits autophagy and improves recovery in spinal cord injury
HK1190652B (en) Decorin for use in treating traumatic neurological conditions via intrathecal administration
Gunay et al. The effectiveness of tetanus toxin on sciatic nerve regeneration: a preliminary experimental study in rats
Milton Chronic Systemic Manipulation of Axonal Inhibitory Perineuronal Net and rPTPσ Promotes Forelimb Recovery and Neuroplasticity
Sanghvi et al. Chondroitinase ABC in neural regeneration: advances in CNS and peripheral nerve repair
Shanmugalingam Exploring novel molecular approaches to promote repair of the damaged nervous system: A role for Neuronal Pentraxin 2
Manoukian Biopolymer-nanotube Nerve Guidance Conduit Drug Delivery for Peripheral Nerve Regeneration
US20250288645A1 (en) USE OF GsMTx4 AND GsMTx4 CONJUGATES TO IMPROVE RECOVERY FROM JOINT INJURY
JP2001511136A (ja) Ｃｍ１０１／ｇｂｓ毒素による神経損傷の修復の促進
Ashour et al. Tissue-Engineered Neural Stem Cell Scaffolds in Spinal Cord Injury: Insights into Materials, Molecular Pathways, and Regenerative Applications
Lipponen The Effect of Intrathecally Administered HB-GAM (Pleiotrophin) in the Cervical Hemisection and Cervical Hemicontusion Mouse Models of Spinal Cord Injury

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141217

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151207

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160204

R150 Certificate of patent or registration of utility model

Ref document number: 5883027

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250